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Abstract  
Objectives: Assessing the clinical effectiveness of a topical sialogogue on spray (malic acid, 1%) in the treatment 
of xerostomia induced by antihypertensive drugs. 
Study Design: This research has been carried out through a randomized double-blind clinical trial. 45 patients suffer-
ing from hypertensive drugs-induced xerostomia were divided into 2 groups: the first group (25 patients) received a 
topical sialogogue on spray (malic acid, 1%) whereas the second group (20 patients) received a placebo. Both of them 
were administered on demand for 2 weeks. Dry Mouth Questionnaire (DMQ) was used in order to evaluate xeros-
tomia levels before and after product/placebo application. Unstimulated and stimulated salivary flows rates, before 
and after application, were measured. All the statistical analyses were performed by using SPSS software v17.0. Dif-
ferent DMQ scores at the earliest and final stage of the trial were analysed by using Mann-Whitney U test, whereas 
Student’s T-test was used to analyse salivary flows. Critical p-value was established at p<0.05. 
Results: DMQ scores increased significantly (clinical recovery) from 1.21 to 3.36 points (p<0.05) after malic acid 
(1%) application whereas DMQ scores increased from 1.18 to 1.34 points (p>0.05) after placebo application. After 
two weeks of treatment with malic acid, unstimulated salivary flow increased from 0.17 to 0.242 mL/min whereas 
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Introduction
Xerostomia is a subjective complaint of dry mouth, and 
it is usually caused by a decreased salivary flow or by 
changes in the biochemical composition of saliva. Pa-
tients suffering from xerostomia usually complain about 
difficulties when chewing, swallowing or even speak-
ing, particularly those with dental prosthesis. Where-
as xerostomia is a subjective concept, hyposalivation 
makes reference to a decreased salivary flow and it is, 
therefore, an objective and measurable variable (1-3).
Hyposalivation is considered to appear when salivary 
flow rates are under 0.1-0.2 mL/min (unstimulated) or 
0.7 mL/min (stimulated). Xerostomia is often associ-
ated with hyposalivation, but not always. It is widely 
accepted that a salivary flow rate reduction of around 
50% implies the manifestation of signs and symptoms 
of xerostomia (4,5). However, some cases have been de-
scribed in patients with a normal salivary flow rate. Fur-
thermore, other patients with a decreased salivary flow 
rates (generally fewer than 50% if compared to normal 
levels) have not complaint about oral problems.
The most important aetiological factors related to xeros-
tomia are: head and neck radiotherapy, some systemic 
conditions (primary or secondary Sjögren syndrome, 
stress, diabetes, clinical depression ) and also the intake 
of certain drugs (1,6,7). More than 500 drugs (8), includ-
ing 42 different pharmacological groups (9) can cause 
xerostomia as a side effect. Drugs with the most intense 
xerostomizing effect are: -those with a direct impact on 
the autonomic nervous system, which regulates gland 
secretions (anticholinergic agents; adrenergic blockers); 
- those with an indirect impact on the central nervous 
system (antipsychotic drugs, anxiolytic agents); - those 
which increase the excretion of liquids, particularly diu-
retics. In addition to this, some psychological factors, 
such as stress, anxiety or depressive conditions are also 
related to xerostomia. However, hiposalivation is nor-
mally associated with drug-induced xerostomia, where-
as this association is not usual in the case of xerostomia 
related to psychological conditions (10).
Drugs most commonly associated with xerostomia are: 
-antidepressants (particularly tricyclic antidepressants) 
(11); - Selective Serotonin Reuptake Inhibitors (SSRIs), 
particularly when combined with benzodiazepines (12); 
-Diuretics, antihypertensive drugs and angiotensin-
converting enzyme inhibitors (ACE inhibitors), -oral 
hypoglycemiants,-acetylsalicylic acid (ASA), -iron sup-
plements. Let us not forget that drugs with the most 
intense xerostomizing effect are also the most widely 
and frequently used (treatment of metal disorders and 
cardiovascular diseases) (13). This fact is useful to ex-
plain the important prevalence among adults older than 
65 (20-46%) (6,14,15). Such prevalence is caused by 3 
important factors: accumulation of systemic conditions, 
polymedication and the progressive decline of salivary 
gland parenchyma.
There is a wide range of therapies in the treatment of 
xerostomia (sialogogues, salivary substitutes, general 
measures…), although the efficiency of many of them is 
controversial (1,6,7). Abundant literature has described 
malic and citric acid as salivary stimulants, although 
they were dropped out because their demineralizing ef-
fect on the tooth enamel (16,17). Nevertheless, recent 
researches have reported a decrease of this deminera-
lizing potential of malic acid, if used at an appropri-
ate concentration (4.7%) and combined with xylitol and 
fluorides (18).
Assessing the clinical efficiency of a topical sialogogue 
on spray (malic acid 1%), combined with xylitol and 
fluoride, in the treatment of xerostomia induced by an-
tihypertensive drugs for 2 weeks has been the main ob-
jective of this research.
Material and Methods
-Patients recruitment and intervention 
This randomized double-blind clinical trial has been 
approved by the University of Granada Ethics Com-
mittee (Spain). Randomization was done following 
the guidelines of The Consort Statement (http://www.
consort-statement.org/consort-statement/). The sam-
ple size calculation was performed from the standard 
deviation of the main variable (DMQ). 45 participants 
with xerostomia caused by the chronic admnistration of 
antihypertensive drugs, were recruited at the Faculty of 
Dentistry of the University of Granada (Spain) and also 
at the Faculty of Medicine and Dentistry of the Univer-
sity of Murcia (Spain). No participants left the trial.
-Inclusion Criteria
-Subjects under antihypertensive treatment (longer than 
one month) with xerostomia.
-Exclusion Criteria
-History of head and neck radiotherapy, Sjögren’s syn-
drome and related autoimmune diseases (rheumatoid 
the stimulated one increased from 0.66 to 0.92 mL/min (p<0.05). After placebo application unstimulated flow ranged 
from 0.152 to 0.146 mL/min and stimulated flow increased from 0.67 to 0.70 mL/min (p>0.05). 
Conclusions: Malic acid 1% spray improved antihypertensive-induced xerostomia and stimulated the production 
of saliva.
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arthritis, polyarthritis nodosa, systemic sclerosis or lu-
pus erythematosus).
-Subjects with diabetes and/or oral hypoglycemic therapy.
-Chronic alcoholic subjects
The 45 patients suffering from hypertensive drugs-
induced xerostomia were divided into 2 groups: the 
first group (25 patients) received a topical sialogogue 
on spray (malic acid, 1%) whereas the second group 
(20 patients) received a placebo. 16 patients were being 
treated with diuretics, 14 with angiotensin-converting 
enzyme inhibitors (ACE inhibitors), 7 with non-selec-
tive beta-blockers, and 8 with angiotensin II receptor 
antagonists.
The randomized distribution was designed by using the 
websitehttp://www.randomization.com, and obtaining 
a randomization plan, which assigned participants to a 
“test group” (to be treated with 1% malic acid on spray) 
or to a “placebo group” (to be treated with a spray with 
no malic acid). This randomization plan was delivered 
to a person not related to the project in order to prevent 
both participants and observers from identifying the 
product.
Once the patients had signed the informed consent form 
and anamnesis had been performed, the following ques-
tion was asked to every patient: “How often do you feel 
dry mouth?” Available answers were: “never”, “some-
times”, “usually” or “always”. Those who answered 
“usually” or “always” were considered as suffering 
from xerostomia.
Our clinical intervention was based on the application 
of a topical sialogogue, containing 1% malic acid (Xeros 
Dentaid spray©, Dentaid, Barcelona,  Spain) for 2 weeks 
in an experimental group of 25 patients, whereas a con-
trol group of 20 patients was given a placebo with the 
same presentation and composition (excepting malic 
acid). Product/placebo was presented without any brand 
name, and they were administered on demand, with a 
maximum of 8 doses per day. 
Dry Mouth Questionnaire (DMQ)
DMQ, developed by Vissink et al. (19), Gravenmade et 
al. (20), van der Reijden et al. (21) y Regelink et al. (22) 
(Table 1), was used in order to obtain subjective infor-
mation about the severity of xerostomia before and after 
treatment with malic acid/placebo. Every participant 
had to answer an initial questionnaire (DMQ 1) about 
the symptoms related to oral dryness, and received a 
spray (malic acid or placebo). After 2 weeks of treat-
ment, patients had to answer again DMQ 1, and also a 
new questionnaire (DMQ 2) about the efficiency of the 
treatment.
DMQ 1 was used to assess the initial severity of oral 
dryness, particularly its impact on oral function: prob-
DMQ 1 
The questions have to be completed both at baseline and after two weeks of use of the agent 
Question       Response (scale 0-4)
How dry is your mouth?     VERY DRY-NOT DRY 
Are you suffering from oral dryness during daytime?                 VERY SEVERE-NEVER 
Are you suffering from oral dryness at night?                  VERY SEVERE-NEVER 
Do you have a nasty taste in your mouth?    VERY SEVERE-NEVER 
Is sleeping impeded?      VERY SEVERE-NEVER 
Is swallowing impeded?      VERY SEVERE-NEVER 
Is eating impeded?                                                                                 VERY SEVERE-NEVER 
DMQ 2  
Questions have to be completed after two weeks of use of the agent 
Question        Response (scale 0-4)
How frequently do you apply the substitute?              ?? TIMES PER DAY 
For how long is your mouth moist after applying the substitute?            ?? MIN 
Is the extent of oral dryness reduced when applying the substitute? HIGHLY-NOT REDUCED 
How dry is your mouth when applying the substitute?                  VERY SEVERE-NOT DRY 
How do you appreciate the taste of the substitute?              VERY PALATABLE-NASTY 
What complaints are reduced when using the substitute? 
               Dryness during daytime                 HIGHLY-NOT REDUCED 
 Dryness at night                  HIGHLY-NOT REDUCED 
 Burning mouth                  HIGHLY-NOT REDUCED 
 Nasty taste                  HIGHLY-NOT REDUCED 
 Sleeping difficulties                 HIGHLY-NOT REDUCED 
 Difficulties with speech                 HIGHLY-NOT REDUCED 
 Difficulties with swallowing                 HIGHLY-NOT REDUCED 
                Difficulties with eating                                                       HIGHLY-NOT REDUCED 
Table 1. Dry Mouth Questionnaire (DMQ).
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lems when chewing, swallowing, speaking and impact 
on daily life.
DMQ 1 used a 0-to-4 rating scale where 0 = “very dry” 
and 4 = “not dry at all”. After 2 weeks of treatment, DMQ 
1 was repeated (Table 1). On the other hand, DMQ 2 was 
designed to assess the impact of the spray on the symp-
toms of xerostomia, and was also based on a 0-to-4 rating 
scale where 0 = frequent restriction of oral function and 
4= no restriction of oral function/ no oral dryness feeling. 
Application frequency and retention time inside the oral 
cavity were also registered (Table 1).
-Sialometries
As secondary measures, both unstimulated and stimu-
lated salivary flow rates were assessed in all patients. 
Unstimulated salivary flow rate was obtained through 
the collection of saliva every 30 seconds during 15 mi-
nutes. Saliva was collected on 20mL plastic containers, 
which were pre-weighted (0.001 g) by using a precision 
scale (Cobos M-150, Cobos, Barcelona,  Spain). Meas-
ures were expressed as mL/min. As far as stimulated 
flow rate is concerned, it was obtained by chewing a 1 g 
piece of paraffin during 6 minutes. Saliva collected dur-
ing the first minute was discarded, and then collected 
on containers every 30 seconds. DMQ and sialometries 
were always performed from 09:00 a.m. to 11:00 a.m. in 
order to avoid any circadian variation. Prior to interven-
tion, patients were told not to eat, drink, smoke or brush 
their teeth from one hour before their visit.
-Statistical analysis
All of the analyses were performed by using SPSS soft-
ware v17.0 (SPSS Inc. Chicago, IL, USA). The main 
purpose was to contrast different DMQ scores at the 
earliest and final stage of the clinical trial by using the 
Mann-Whitney U test. Student’s T-test was used to 
analyse both unstimulated and stimulated salivary flow 
rates. Critical p-value was established at p<0.05.
Results
Table 2 shows the results of our clinical trial in rela-
tion to age, gender, DMQ score (oral dryness feeling), 
number of applications and duration of sialogogue ac-
tion. No relevant statistical differences were found as 
far as gender is concerned. DMQ scores related to dry 
mouth feeling increased significantly (therefore sug-
gesting a clinical recovery) from 1.21 ± 0.14 points to 
3.36 ± 0.17 points (p<0.05) after two weeks treatment 
with malic acid, whereas in the control group DMQ 
scores increased from 1.18 ± 0.12 points to 1.34 ± 0.09 
points (p>0.05). 92% of the patients treated with malic 
acid experienced some clinical recovery, in contrast to 
just 15% of the patients treated with placebo. Moreover, 
no patient in the experimental group experienced a de-
cline of the initial condition, whereas 3 members of the 
control group did it. Patients belonging to the experi-
mental group used the product 3.71± 1.32 times per day, 
VARIABLES EXPERIMENTAL GROUP
CONTROL
GROUP
Sample size  25 20 
Age (years) 54,3 ± 4,3 51,8 ± 3,4 
Gender   
 Male 11 9 
 Female 14 11 
DMQ score    
           0 weeks 1,21 ± 0,14 1,18 ± 0,12 
           2 weeks   3,36 ± 0,17* 1,34 ± 0,09 
Number of applications  3,71± 1.32* 6,75 ± 1,21 
Length of Effect (minutes)   29,6 ± 1,25* 5,80 ± 1,10 
Table 2. Age, gender, DMQ score (severity of xerostomia) and 
length of effect of the participants. Average ± standard deviation.
* p < 0,05
whereas those belonging to the control group used the 
placebo 6.75 ± 1.21 times per day.
Regarding salivary flow rates, they improved after 
treatment with 1% malic acid. After 2 weeks of treat-
ment with the product, unstimulated salivary flow rate 
increased significantly from 0.170 mL/min to 0.242 mL/
min (p<0.05), whereas patients treated with placebo 
ranged from 0.152 mL/min to 0.146 mL/min (p>0.05) 
(Fig. 1). As far as stimulated salivary flow rates are con-
cerned, patients treated with malic acid experienced 
a significant average increase from 0.660 mL/min to 
0.920 mL/min after 2 weeks treatment (p<0.05); where-
as those patients treated with placebo experienced an 
average increase from 0.67 mL/min to 0.70 mL/min af-
ter 2 weeks (p>0.05) (Fig. 2).
Discussion
The most important aetiological factor related to xeros-
tomia is the intake of drugs. The interruption of the 
treatment or substitution of these drugs could increase 
the salivary flow rate to the level previous to treatment. 
Nevertheless, this practice involves a risk for the health 
of the patient, as it would improve oral dryness but would 
also aggravate the previous condition (in our research, 
this previous condition is arterial hypertension). 
Xerostomia induced by hypertensive drugs is reversible, 
since even with this condition the salivary glands are 
sufficiently functional. Consequently, they can be treated 
with salivary stimulants (sialogogues). Treatment with 
systemic sialogogues with anticholinesterasic and cholin-
ergic action represents an efficient therapeutic option, al-
though they are usually dropped out because of the quan-
titative and qualitative importance of their side effects. In 
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Fig. 1. Average and standard deviation of unstimulated salivary flow rates of the participants (at the beginning and after two weeks of 
treatment). 
Fig. 2. Average and standar deviation of stimulated salivary flow rates of the participants (at the beginning and after two weeks of treat-
ment).
this context, the application of topical sialogogues can be 
a useful alternative in the treatment of reversible xeros-
tomia induced by drugs, as in spite of the fact that their 
therapeutic effects are more transitory and less lengthy; 
their side effects are also less powerful (23).
The application of topical sialogogues containing acids 
in the treatment of xerostomia is not recent. However, 
continuous application of substances such as citric acid 
(24) has been related to an increased risk of caries, as a 
consequence of the erosive action of these agents over 
the dentin. Similarly, the use of chewing gums contain-
ing 0.06 mg of ascorbic or malic acid combined with 
important quantities of sorbitol and mannitol (16) can 
cause similar negative effects. 
All of these products were dropped out because of their 
demineralising effect on the human dentin, effect not 
only caused by the high doses of acidic products, but 
also by the product presentation (chewable products), 
which allows a lengthy contact with the dental surfaces. 
In order to solve this, presentation in spray format al-
lows a fast and direct contact with the oral mucosa, and 
this fact, if combined with a suitable concentration (as 
the stimulant effect on saliva production is not altered 
by it), could reduce the demineralising potential of these 
substances (25,26,18).
According to the researches carried out by da Mata et 
al. (18) the use of 4.7% malic acid on spray (combined 
with fluorides and xylitol), on 60 healthy subjects in-
duced a significant drop of salivary pH levels, which re-
covered 20 minutes later. Nevertheless, when this acidic 
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salivary stimulant contains xylitol/fluorides, the subse-
quent decrease in the salivary pH level never reaches a 
score lower than 5.5 (hydroxyapatite critical level) (18). 
Thus, combination of malic acid with xylitol/fluorides 
on spray seems to be a safe option as topical sialogogue 
(9). According to the results of our clinical research, the 
use of malic acid as a salivary stimulant, if combined 
with xylitol and fluorides, can be a valid option in the 
treatment of mild and reversible xerostomia induced by 
antihypertensive drugs. Malic acid acts as a substance 
capable of generating a sour taste gustatory stimulus. Its 
mechanism of action is linked to dissociation of malic 
acid in H+, which they join water to become hydronium 
ions (H3O
+); this action generates a stimulation of sali-
vary secretion to dilute the concentration of acids in the 
oral cavity. Xylitol and fluorides do not stimulate saliva 
but they reduce erosion and cariogenic potential.
When used as a topical sialogogue, this product pro-
vides a short term effect increasing salivary flow rates 
immediately and subjects in this clinical trial reported 
a feeling of increase saliva production for an average 
period of 29 minutes (in contrast to an average period of 
5 minutes in the control group). These results are in line 
with the results obtained by da Mata et al. (18).
Salivary flow rates became normal 20-30 minutes after 
application, and patients did not feel the need for a new 
application for around 6 hours time, so 3 or 4 applica-
tions per day were enough. In contrast, patients treated 
with placebo used it 6 or 7 times per day.
Among the different available questionnaires to evalu-
ate the severity of oral dryness, we chose the DMQ (19-
22), since it is an easy and fast method to assess the 
efficiency of the product. In addition to this, its 0-to-4 
scale can be easily replaced by a Visual Analogue Scale 
(VAS) of 10 cm. Therefore, DMQ has been a valid and 
useful tool for the carrying out of our clinical trial.
The results of our randomized clinical trial clearly 
show a significant increase of salivary flow rates, both 
unstimulated and stimulated, after the treatment with 
1% malic acid on spray. These results are in accordance 
with those obtained by da Mata et al. (18), although we 
must point out that in that research, the subjects were 
healthy individuals who were not suffering from xeros-
tomia. No additional researches or studies have focused 
on the assessment of the efficiency of malic acid in the 
treatment of xerostomia, so our clinical trial is one of 
the first ones dealing with this topic.
As far as subjective improvement of xerostomia is con-
cerned, there are not similar papers to compare the 
results of our trial, as research in this field has been 
neglected because of the caries-inducing role of acidic 
substances when they are not properly formulated. In 
this sense, our clinical trial is a pioneering work in the 
field of treatment of xerostomia induced by drugs with 
topical acidic salivary stimulants.
The results of our clinical trial show that the use of 
1% malic acid on spray causes an improvement of dry 
mouth feeling, and stimulates saliva production. Conse-
quently, 1% malic acid may be an effective treatment of 
antihypertensive-induced xerostomia.
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